950 related articles for article (PubMed ID: 19579175)
1. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
Hardeland R
Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
[TBL] [Abstract][Full Text] [Related]
2. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
Neubauer DN
Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
[TBL] [Abstract][Full Text] [Related]
3. Tasimelteon for insomnia.
Lankford DA
Expert Opin Investig Drugs; 2011 Jul; 20(7):987-93. PubMed ID: 21548834
[TBL] [Abstract][Full Text] [Related]
4. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs.
Srinivasan V; Spence DW; Pandi-Perumal SR; Trakht I; Cardinali DP
Travel Med Infect Dis; 2008; 6(1-2):17-28. PubMed ID: 18342269
[TBL] [Abstract][Full Text] [Related]
5. Investigational melatonin receptor agonists.
Hardeland R
Expert Opin Investig Drugs; 2010 Jun; 19(6):747-64. PubMed ID: 20408738
[TBL] [Abstract][Full Text] [Related]
6. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
Bonacci JM; Venci JV; Gandhi MA
J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
Stahl SM
CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
[TBL] [Abstract][Full Text] [Related]
8. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
9. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
Johnsa JD; Neville MW
Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
[TBL] [Abstract][Full Text] [Related]
10. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
Med Lett Drugs Ther; 2014 Apr; 56(1441):34-5. PubMed ID: 24759294
[No Abstract] [Full Text] [Related]
11. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
[TBL] [Abstract][Full Text] [Related]
12. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
Nishimon S; Nishimon M; Nishino S
Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
[TBL] [Abstract][Full Text] [Related]
13. Tasimelteon: first global approval.
Dhillon S; Clarke M
Drugs; 2014 Mar; 74(4):505-11. PubMed ID: 24610704
[TBL] [Abstract][Full Text] [Related]
14. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
[TBL] [Abstract][Full Text] [Related]
15. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.
Pandi-Perumal SR; Srinivasan V; Poeggeler B; Hardeland R; Cardinali DP
Nat Clin Pract Neurol; 2007 Apr; 3(4):221-8. PubMed ID: 17410109
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
Torres R; Kramer WG; Baroldi P
J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
[TBL] [Abstract][Full Text] [Related]
17. Tasimelteon: a selective and unique receptor binding profile.
Lavedan C; Forsberg M; Gentile AJ
Neuropharmacology; 2015 Apr; 91():142-7. PubMed ID: 25534555
[TBL] [Abstract][Full Text] [Related]
18. [Melatonin--a natural hypnotic?].
Saletu B
Wien Klin Wochenschr; 1997 Oct; 109(18):714-21. PubMed ID: 9441514
[TBL] [Abstract][Full Text] [Related]
19. Ramelteon: new drug. Insomnia: no role for risky placebos.
Prescrire Int; 2008 Oct; 17(97):183-6. PubMed ID: 19534018
[TBL] [Abstract][Full Text] [Related]
20. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders.
Pandi-Perumal SR; Trakht I; Spence DW; Srinivasan V; Dagan Y; Cardinali DP
Nat Clin Pract Neurol; 2008 Aug; 4(8):436-47. PubMed ID: 18628753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
